Experts call for greater urgency in MS treatment
October 7, 2015Research and Development multiple sclerosis
A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
PROFILE: Ambitious Ferring wants to be global fertility leader
October 7, 2015Manufacturing and Production, Research and Development Ferring, peptides
The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …
AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn
October 7, 2015Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions
AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …
Akebia passes vadadustat for anaemia phase III study with FDA & EMA
October 7, 2015Research and Development Akabia, FDA, anaemia
Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …
Rondo AG appoints Joachim Hoeltz as chief exec
October 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Joachim Hoeltz has been appointed chief executive at pharmaceutical packaging company Rondo AG within the Business Area Medipak Systems. He …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial
October 7, 2015Research and Development Genzyme, MS, Sanofi
Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …
FDA approves Alkermes schizophrenia treatment
October 6, 2015Research and Development Alkermes, Aristada, FDA, schizophrenia
The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …
Flu jab reduces risk of stroke for two months
October 6, 2015Research and Development flu vaccine, stroke
The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a …
Moving forward in diabetes
October 6, 2015Research and Development Novo Nordiak, diabetes
As many as 387 million people worldwide are living with diabetes, and it is predicted that by 2035 more than …
Novo Nordisk and Diabetes UK extend ‘Clinical Champions’ initiative
October 6, 2015Medical Communications Novo Nordisk, diabetes
Diabetes UK and Novo Nordisk have announced the appointment of 20 Diabetes UK ‘Clinical Champions’, who will be supported and …
David Luther joins MISSION Therapeutics
October 6, 2015Manufacturing and Production, Medical Communications, Sales and Marketing
Cambridge, UK-based MISSION Therapeutics has announced the appointment of David Luther as chief financial officer.Luther brings more than 25 years’ …
Baxter recalls saline after mould contamination
October 6, 2015Manufacturing and Production baxter
Following a number of recalls earlier this year, Baxter has recalled potentially a further 140,000 bags of sodium chloride due …
UK tops Quality of Death rankings
October 6, 2015Medical Communications NHS, ageing population, palliative care
The UK has ranked first in the 2015 Quality of Death Index, a measure of the quality of palliative care …
Cardinal Health completes $1.944bn acquisition of J&J’s Cordis
October 6, 2015Manufacturing and Production, Sales and Marketing Cardinal Health, Cordis, mergers and acquisitions
Cardinal Health has completed the acquisition of Johnson & Johnson’s Cordis business: a global leader in cardiology and endovascular devices, …
Pfizer axes lay-off plans and creates new jobs
October 6, 2015Manufacturing and Production Pfizer
A Pfizer facility in Ireland that was set to close has now been taken off the list of facilities no longer needed …
Desktop device synthesising lidocaine could revolutionise pharma manufacturing
October 6, 2015Manufacturing and Production lidocaine
A novel device with the ability to produce one of the most in-demand anaesthetics in any location may set the …
After Daraprim, Turing Pharma submits first in-house candidate to FDA
October 6, 2015Manufacturing and Production, Research and Development turing
Turing Pharma may have been on the end of some less-than-favourable media coverage in recent weeks, but the company is …
Teva acquires Mexico’s Rimsa for $2.3 billion
October 5, 2015Research and Development, Sales and Marketing Mexico, Rimsa, Teva, mergers and acquisitions
Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of …
North 51 acquired by Bionical
October 5, 2015Bionical, North 51, mergers and acquisitions
North 51 Ltd, a Nottingham-based healthcare company has been acquired by Bionical in a multi-million pound deal. The North 51 …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
